After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GSK PLC closed 20.84% below its 52-week high of £18.24, which the company achieved on May 16th.

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

Apollon Wealth Management LLC raised its stake in shares of GSK plc (NYSE:GSK – Free Report) by 9.8% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...